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INTRODUCTION 
 1 
EPIDEMIOLOGICAL STUDY OF NON STRUCTURAL 
CAUSES 
ABNORMAL UTERINE BLEEDING 
 
 
INTRODUCTION 
 The most common presenting complaint encountered in the 
Gynecological practice, its incidence accounting as much as 30-40%. 
The availability of diagnostic tools such as ultrasound, clinical 
endometrial sampling and diagnostic hysteroscopy has made it 
possible to promptly diagnose and treat an increasing number of 
menstrual disorders is an office setting. 
Menstruation is a cyclical phenomenon that routinely begins at 
menarche and ends at menopause.  The normal menstrual rhythm is 
regulated and modulated by the hormones secreted by hypothalamus, 
pituitary and ovaries. 
  
 
REVIEW OF 
LITERATURE 
 2 
REVIEW OF LITERATURE 
DEFINITION 
 Any bleeding from genital tract which is a deviation from normal 
in frequency, cyclicity or quantity. 
INCIDENCE 
In 10 – 30 % of reproductive age group of this 50 % is 
perimenopausal age group  gives the history (Haynes 1971, Prentic 
2000) 
Premenopausal age group – Precocious puberty / accidental 
exogenous ingestion of drugs / ovarian neoplasms, need pelvic 
examination (Quint 2001). 
NOMENCLATURE 
 Menorrhagia mensus more than 7 days, more than 80 ml blood 
loss as per (Hallberg, 1966.) 
 Wallberg (1966) technique to extract haemoglobin from sanitary 
napkins using sodium hydroxide.can easily assess the blood loss  
 Objective perception of blood loss  of individuals  is to define 
menorrhagia  (Chimbra 1980, Fraser 1984). 
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Warner and Collegues (2004) Positive correlation of menorrhagia 
with passing clot 1.1 inches in diameter and changing pads more 
frequently than every 3 hours. 
ADOLESCENCE   
 An ovulation -dysfunction and the coagulation defects at 
disproportionately higher levels compared to reproductive age 
(Classens 1981, Oval 2001, Smith 1998). 
 Reproductive age group 1 : 20 life time risk (Bangers 2004). 
 Perimenopausal age group :  70 % of gynaecological visit 
 Seltzer and Colleagues reviewed the 500 perimenopausal age 
group with  AUB. 18 % had menorrhagia, metorrahagia and one fifth 
were premalignant. 
MENOPAUSE  
 Choo and Colleague 1985 – Majority   post menopausal bleeding 
were due to atropy of endometrium, malignancy most commonly. 
Neuro Anatomy 
 Hypothalamus is a small neural structure situated at the base 
of the brain above optic chiasma and below the third ventricle.   It is 
directly connected to pituitary gland and is the part of brain. 
Hypothalamus is well supplied and nourished by superior 
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hypophyseal and inferior hypophyseal arteries.  Hypothalamus is 
regulated by 3 feedback loops.  
1. Long acting Loop : Steroid hormones from ovary and 
androgens acting on hypothalamus. 
2. Short acting feedback loop : Pitutary hormones. 
3. Ultra Short Acting Loop : Within the secretions of 
Hypothalamus 
Hypothalamus : The major secretary products are 
J Gonadotrophin releasing hormone (GnRH) which controls and 
modulates the secretions of lutenizing hormone.  LH and follicle 
stimulating hormone (FSH) 
J Corticotropin hormone releasing hormone (CRH) controls 
and modulates the release of (ACTH) Adrenocorticotropic 
hormone. 
J Growth hormone releasing hormone (GHRH) which regulates 
and modulates the release of growth hormone. 
J Thyrotrophin releasing hormone (TRH) which regulates the 
secretion of thyroid stimulating hormone. 
Hypothalamus is kept dormant under the inhibition of adrenal 
cortex and temporal lobe. 
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1. Emotional stress tends to stimulate or inhibit HPO axis 
2. Ephedrine and serotonin tends to stimulate HPO axis 
3. Serotonins and opiates tends to inhibits HPO axis 
4. Gonadotrophin’s also tends to inhibit HPO axis 
 GnRH secreted by median eminence and the arcuate nucleus 
which modulates secretory activity of FSH and LH.  It also secretes 
prolactin inhibiting factor which inhibits the release of prolactin. 
 GnRH is a decapeptide with a half life 2-4 min.  It is released in 
pulsatile manner into portal vessels and reaches anterior pituitary 
gland.  In preovulatory phase, pulse is once in 60 minutes. In luteal 
phase once in 3 hours with increased amplitude. 
Pituitary gland 
Pituitary gland lies in sella turcica.  It comprises of anterior or 
posterior pituitary  
FSH  
Follicle stimulating hormone is water soluble, glycoprotein of 
high molecular weight which is secreted by βcells.  FSH controls the 
ripening of the primordial follicles and is conjunction with the LH it 
activates.  Secretions of Estrogen. Half life of FSH is 4 hours. Estrogen 
suppresses FSH secretion. It develops LH receptors in the granulosa 
cells. 
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LH 
 Luteinizing hormone is another water soluble glycoprotein of 
high molecular weight secreted by β cells.  Along with FSH it activates 
the secretion of estrogen brings about the maturation of ovum and 
causes ovulation and then completes reduction division of oocyte. 
Endogenous Opiods and Effects on GnRH 
1. Endorphins usually have endogenous morphine like activity 
inhibits regulation of temperature, appetite and behaviour. 
2. Enkephalins – have the main function is to regulate 
autonomous nervous system. 
3. Dynorphins – similar to endorphins produces behavioral 
changes and high analgesic property. 
4. Endorphins inhibit GnRH in hypothalamus thereby decreasing 
gonadotrophins. 
5. Ovarian sex steroids can increase central endorphins thereby 
decreasing gonadotrophins. 
Prolactin – 198 amino acid polypeptide secreted by anterior 
pituitary in under the inhibitory control of hypothalamic secretion of 
dopamine increased prolactin levels cause amenorrhoea and 
galactorrhoea.  prolactin secretion is stimulated by breast 
manipulation, drugs, stress, exercise, TRH, vasopressin, γGABA 
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dopamine, βendorphins.  VIP, Epidermal growth factor, angiotensin, 
TRH – Thyrotrophic Releasing hormone is also synthesized primarily 
from the arcuate nucleus of hypothalamus. 
Normal Menstural Cycle 
 Normal menstural rhythm occurs once in 28 days cycle.  First 
day of mensturation refers to day 1 of menstural cycle.  Menstural 
cycle consists of ovarian cycle and endometrial cycle.  Ovarian cycle 
includes follicular phase during which all the ovarian follicles develop 
and Luteal phase during which corpus Luteum forms and later 
regresses.     Day 1-14 of the cycle is the follicular phase. Day 14-28 is 
called the luteal phase.  Endometrial cycle consists of proliferative and 
secretory  phase corresponding to the two cycles of ovary. 
Sequence of changes during menstural cycle 
1. Under the effect of tonic pulsatile secretion of LH throughout 
the folicular phase of the cycle the theca cells synthesise 
androstenedione. 
2. This is transferred to the granulosa cells where FSH stimulated 
aromatase action induces estrogen secretion. 
3. This exerts a negative feedback loop on the pituitary and 
hypothalamus thereby reducing FSH levels. 
4. High levels of estrogen trigger LH surge simultaneously. 
 8 
5. LH surge trigger ovulation 
6. Theca cells of the corpus luteum secrete progesterone. 
7. Luteinised granulosa cells of the corpus luteum secrete estrogen 
leading to the second estrogen phase 
8. Estrogen and progesterone concentrations decrease with the 
demise of corpus luteum in the late luteal phase. 
Endometrial Function and Molecular Biology 
 Cyclical shedding of endometrium resulting in menstruation is a 
unique function of the uterus. 
Steroid Hormone Receptors 
 Steroid receptors are proteins that are found in the cytoplasm or 
nucleus of eukaryotic cells which bind to and regulate the 
transcription of DNA under the regulation of steroid hormones. 
The hormone gene superfamily is divided into three functionally 
distinct subfamilies.  These subfamilies are: 
Type I are classical steroid hormone receptors which include the 
glucocorticoid receptors (including CORT receptor), androgen 
receptors, mineralcorticoid receptors (including ALDO receptor) and 
progesterone receptor. 
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Type II consists of thyroid hormone related receptors including T3R, 
RAR, RXR and VDR. 
Type III is formed by the ER (estrogen receptor) and a few orphan 
receptors. 
Estrogen Receptors 
 17-β estradiol is  the most biologically potent naturally 
occurring estrogen, is secreted by the granulosa cells of dominant 
follicle and luteinized granulosa cells of the corpus luteum.  Estradiol 
action is complex and appears to involve two classical nuclear 
hormone receptors. Gustafsson review (1999) shows the 
distribution of ERα and ERβ.Estradiol and other bioactive estrogens 
cause the replication of the endometrium indirectly i.e. through action 
of stromal cells through their receptors.  ERβ is mostly expressed in 
glands, stroma and vascular cells of the endometrium. ERβ levels are 
highest during the proliferative phase of the cycle. 
Progesterone Receptor 
 Progesterone mainly acts through nuclear hormone receptors. 
Progesterone enters cells by diffusion in responsive tissues.  There are 
two isoforms of the human progesterone receptor 
Progesterone receptor type A (PR-A) 
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Progesterone receptor type B (PR-B); Both arise from a single gene 
(chromosome 11q22). 
Endometrial Cycle  
Proliferative Phase 
Follicular –phase production of estradiol is the most important 
factor in recovery of the endometrium following menstruation.  Stroma 
cell proliferation appears to increase through paracrine and autocrine 
action of estrogen and increased local levels of fibroblast growth 
factor-9 (Tsai et al., 2002).  Estrogens also increase local production of 
vascular endothelial growth factor (Sugino et al., 2002) which causes 
angiogenesis through the elongation of vessels in the basalis. 
Secretory Phase 
 After ovulation the estrogen-primed endometrium responds to 
rising levels of progesterone in a highly predictable manner.  By day 
17, glycogen accumulated in the basal portion of the glandular 
epithelium creating subnuclear vacuoles and pseudostratification. 
This is the result of the direct progesterone action through 
progesterone receptors expressed in the glandular cells. 
 Estradiol action is also decreased because of glandular 
expression of type-2 form of 17β-hydroxysteroid dehydrogenase, which 
converts estradiol to the less active estrogen, estrone. 
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Menstruation 
 The events leading to menstruation are initiated as a result of 
the withdrawal of progesterone following luteolysis or corpus luteum, 
many of the molecular mechanisms involving endometrial 
progesterone withdrawal as well as the subsequent inflammatory 
response that causes the sloughing of the endometrium(Critchley et 
al., 2001). 
 Infiltration of polymorphonuclear leukocytes into the stroma 
occurs on the day or two immediately preceding the onset of 
menstruation which gives a pseudo inflammatory appearance to the 
tissue.  The endometrial stromal and epithelial cells produce 
interleukin-8 (IL-8), a chemotactic activating factor for neutrophil;s. 
This IL-8 helps to recruit neutrophils into the endometrium (Arici 
1993).  The rate of synthesis of IL-8 and MCP-1 in the endometrial 
cells appear to be modulating by circulating sex steroid hormones and 
local production of transforming growth factor β (Arcici 1996 a, 1996 
b). 
 The infiltration of leukocytes is considered key to initiation of 
extra cellular matrix breakdown of the functionalis layer.  The rising 
level of metalloproteinases tips the balance between proteases and 
protease inhibitors, effectively initiating degradation of matrix 
resulting in the initiation of menstruation (Dong et al., 2002). 
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Prostaglandin & Menstruation 
 Prostaglandins are most often synthesized within the same 
tissue in which they act through the autocrine or paracrine 
mechanisms.  They act through a host of separate but specific plasma 
membrane G-protein linked receptors.  A role of prostaglandin, 
especially prostaglandin F2α (PGF2α), which is a vasoconstrictor in the 
initiation of menstruation, has been suggested (Abel 2002). 
Vasoactive Peptides and Menstruation 
 One is the endothelin-enkenphalinase system.  The endothelins 
–ET-1, ET-2, WET-3- are small, 21-amino acid peptides, ET-1 is the 
potent vascoconstrictor, a product of vascular endothelial cells. 
Endothelins are degraded by the enzyme enkephalinase, which is 
localized in endometrial stromal cells and its specific activity is 
proportional to the level of progesterone in blood (Casey et al., 1991). 
Mechanism controlling onset and Cessation of Endometrium. 
J Menstruation is by ischemic necrosis of endometrium caused by 
vasoconstriction of spiral arterioles in the basal layer triggered 
by estrogen and progesterone withdrawal. 
J Histologically menstruating endometrium demonstrates focal 
necrosis inflammators any coagulation rather than the diffuse 
hyalinization and coagulation necrosis expected in hypoxia 
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Classic Concept 
Initiation of menstruation is an enzymatic autodigestion of the 
functional layer of endometrium and its subsurface capillary plexus; 
possibly extending to spiral arteries of basal layer. 
Enzymatic degradation of release of intracellular lysosymal 
enzymes and Proteases from infiltrating inflammatory cells and 
actions of matrix metalloproteinases causes degradation of the 
endometrial cells. 
Arrest of Bleeding depends on 3 mechanisms 
1. Hemostasis by platelet plug and clot formation 
2. Prostaglandins mediated vasoconstriction 
3. Tissue repair 
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1. Hemostasis by platelet plug and clot formation 
 Coagulation cascade starts functioning of endometrium clots 
form on the vessels.  Platelet aggregation leads to platelet plug 
formation once the bleeding stops and allows the fibrinolytic 
activity and favours free flow of menstrual fluid. 
2. Prostaglandins (PG) mediated vasoconstriction 
 Arachidonic acid, a lipid from cell wall is a substrate for the 
synthesis of prostaglandin and enzyme prostaglandin 
synthetase present in the endometrium. 
Phospholipid 
        
Free arachidonic acid 
Estrogen 
Progesterone 
 
PGE2  PGI2  PGF2α TXA2  
 Vasodilator   Vasoconstrictor 
Platelet anti aggregator  Platelet aggregator 
J Estrogen produces PGE2 :  PGF2α 
      1   :    1 
J Progesterone produces PGE2 :  PGF2α 
      1 :    2 
So the bleeding is controlled. 
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3. Tissue repair 
 Re-epithelisation takes place after shedding of endometrium at 
the mouth of basal glands.  Epidermal growth factors, fibroblast 
growth factor, vascular growth factor are the local hormones 
established for tissue repair. 
Adolescent – Abnormal Bleeding (NOVAKS) 
 During the first 2 to 5 years after menarche most cycles are 
anovulatory.  The mean duration of menses is 4 to 7 days.   Last 7 
days the average blood loss per cycle is 35 ml.  Major component of 
menstrual discharge is endometrial tissue. 
Menstrual cycle frequency is 21 – 45 days 
Cycle variation from cycle to cycle is less than adults 
Duration of flow is 4 – 8 days 
Volume of flow is 4 to 80 ml 
 Transition from anovulatory to ovulatory cycles.  During 
adolescence takes place during the first several years after menarche, 
it results from maturation of hypothalamic – pituitary axis.  Most 
adolescents have ovulatory cycle by the end of second year of 
menarche. 
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Causes 
1. Eating disorders (Anorexia nervosa, Bulimia nervosa) 
2. Excessive physical exercises 
3. Chronic illness 
4. Primary ovarian insufficiency  
5. Alcohol abuse 
6. Stress 
7. Thyroid disease (hypothyroidism, hyperthyroidism) 
8. Androgen excess (pcos) 
9. Diabetes mellitus 
10. Coagulopathy 
11. Pregnancy 
12. External hormonal use 
Whom to suspect bleeding disorder 
1. Heavy menstrual bleeding since menarche 
2. Family history of bleeding disorder 
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3. Personal history 
 J Epistaxis in the last year 
J Bruising without injury > 2cm diameter 
J Minor wound bleeding 
J Oral or gastrointestinal bleeding without anatomic causes 
J Prolonged or heavy bleeding after dental extraction 
J Unexpected post operative bleeding 
J Hemorrhage from ovarian cyst 
J Hemorrhage requiring blood transfusion 
J Post partum hemorrhage especially delayed > 24 hr 
Failure to respond to conventional management of menorrhagia. 
Normal menses in reproductive age group 
 Mean duration of menses 4 days average blood loss 35 ml. 
Menstrual cycle frequency is 24 – 38 days 
Duration of flow is 4 – 8 days 
Cycle variation is from cycle to cycle 2 – 20 days 
Volume of flow is 4 to 80 ml 
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Causes 
1. Pregnancy related complaints 
2. Dysfunctional uterine bleeding 
3. Exogenous causes 
4. Fibroid endometriosis 
5. Adenomyosis 
6. Anovulation pcos 
7. Exogenous hormone 
8. Thyroid dysfunction 
9. Medication related – Antipsychotics, coagulant, SSRI 
10. Hepatic / renal causes 
Definitions 
Amenorrhea : Absence of menstruation 
Oligo menorrhea : In frequent irregularly timed 
periods interval > 35 days 
Poly menorrhea : Frequent episodes of menstruation 
intervals < 21 days 
Menorrhagia : Regularly timed episodes of 
bleeding excessive amount > 80 ml 
duration flow > 5 days 
Metrorrhagia : Irregularly timed periods super 
imposed on normal cycle 
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Meno-metrorrhagia : Excessive prolonged bleeding, 
irregularly timed 
Hypomenorrhoea : Regularly timed scanty episodes of 
bleeding 
Inter menstrual bleeding : Bleeding inbetween normal cycle 
Precocious menstruation : Before the age of 10 years 
Post coital bleeding : Vaginal bleeding after intercourse 
Acute emergent AUB : Bleeding characterized by 
hypovolemic shock 
Post menopausal bleeding : >1 year of duration of amenorrhea 
 
Dysfunctional Uterine Bleeding (Jefcottes) 
 Abnormal bleeding from genital tract without any demonstrable 
pelvic pathology and systemic disease.  It is a diagnosis of exclusion 
because of alteration of HPO axis and local changes in prostaglandin 
production. 
DUB is broadly divided into two types. 
Anovulatory Bleeding (80 %) Ovulatory Bleeding (20%) 
Threshold bleeding of puberty Idiopathic ovulatory 
Irregular ripening 
Irregular shedding 
Premenopausal DUB Luteal phase defect 
Metropathia haemorrhagica Following IUCD and post 
sterilisation operation 
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FIGO CLASSIFICATION SYSTEM 
 PALM-COEIN for causes of abnormal uterine bleeding in non-
gravid women of reproductive age group. 
PALM  Structural causes 
  Polyp 
  Adenomyosis 
  Leiomyoma 
  Malignancy 
COEIN Non Structural causes 
  C Coagulopathy 
  O Ovulatory dysfunction 
  E Endometrial 
  I Iatrogenic 
  N Not yet identified 
DUB Previously used for classification systematic or organic 
pathology should be abandoned.  WHO fit into this category have a 
combination of coagulopathy disorder of ovulation and primary 
endometrial disorder. 
Leiomyoma and Malignancy have a FIGO Classification System 
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AUB(C) Coagulopathy 
1. 13 % evidence of Von Willebrand’s disease 
2. Immune thrombocytopenic purpura 
3. Systemic disorder liver and renal diseases 
4. Women using anticoagulants 
Ovulatory Dysfunction [AUB(O)] 
 Ovulatory disorders can contribute to the genesis of AuB 
generally manifesting as a combination of unpredictable timing of 
bleeding and variable amount of flow.  
Endocrinopathies  Polycytic ovary syndrome 
Hypothyroidism  Hyper prolactinemia, mental stress 
Obesity   Hyper prolactinemia, mental stress 
Exercise   Severe athletic training 
Drugs that impact serotonin uptake, phenothiazines, tricyclic 
antidepressants. 
Endometrial (AUB-E) 
 Mechanism regulating endometrial hemostasis deficiencies of 
local production of vasoconstrictors  
1. Endothelin  PGF2α 
2. Accelerated Lysis of endometrial clots by excessive production 
plasminogen activator. 
J Defects in endometrial repair  
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J Inflammation and infection 
J Abnormalities in local inflammatory response 
J aberrations  to endometrial vasculogenesis 
J Demonstration of infection such as chlamydia 
trachomatis & Tuberculosis 
Iatrogenic (AUB-I) 
1. Medicated inert intra uterine system 
2. Gonadal break through bleeding, estrogens, progesterone, 
missed, delayed erratic periods, using along with rifampicin and 
griseofulvin, cigarette smoking can reduce contraceptive effects. 
Women experience unexplained spotting. Intrauterine (LNIUD) 
is first 3-6 months. 
Drugs resulting inhibition of prolactin release causes prolactin 
related disruption consequent disorders of chronic anovulation. 
Not Yet Classified [AUB(N)] 
 AUB in given individual if not yet identified by chronic 
endometritis. AV malformation myometrial hypertrophy, biochemical 
and molecular assays would be defined only by specific assays.  If 
diagnosed, they will be included by appropriate technology. 
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Pictorial Blood Assessment Score 
Score > 100 suggests menorrhagia PBAC Score. 
towel  
1      1 point 1 paise clot 
5      5 point 5 paise clot 
10     5 point flooding 
Points Tampon 
1       
5       
20       
 Semi  quantitative method of blood loss 
 Sensitivity 86 %  Specificity 89 % 
 Jasen et al.,  Revalidated PBAC score > 155 
 Reid et al.,   Doubts on PBAC score validity 
Assessing Blood loss by history 
1. Changing pads <3 hours intervals 
2. > 21 pads / cycle 
3. Multiple pad changes at night 
4. Clots > 1.1 inches 
5. Anemia 
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Bleeding disorders causing AuB 
1. Disorders of platelet adhesion 
i Inherited 
 1. Bernard soulier syndrome 
 2. Von Willebrand’s disease 
 
ii Acquired 
 1. uremia  
 2. Acquired Von Willebrand’s Disease 
2. Disorders of Aggregation 
i Inherited 
 1. Glanzman’s thrombasthenia 
 2. Afibrinogenemia 
ii Acquired 
 1. Fibrin degradation products 
 2. Dysproteinemias 
3. Disorders of granule release 
i Inherited 
 1. Oculo cutaneous albinism 
 2. Chediak Higashi syndrome 
 3. isolated dense S. Granule 
 4. Gray platelet syndrome 
ii Acquired 
 1. cardiopulmonary bypass 
 2. Myeloproliferative disorder 
 3. Drugs aspirin NSAIDS 
 26
Thrombocytopenia  
1. Deceased bone marrow production 
2. Sequestrations of usually enlarged spleen 
3. Increased platelet destruction 
Most common causing menstrual disorders 
Carriers of hemophilia A 
Carriers of hemophilia B 
Von Willebrand’s disease 
fXI deficiency 
Idiopathic Immune Thrombocytopenic purpura 
Idiopathic (Immune) Thrombocytopenic purpura  
 ITP are classified as acute ITP is common in children and 
accounts for 90 % of pediatric causes of ITP.  Mostly recover in 4-6 
weeks.  Acute ITP is rare adult < 10 % of post pubertal system with 
immune thrombocytopenia due to the immune complexes binding 
against the platelet fC fraction or by antibodies against viral antigens. 
Most adults present as chronic ITP Women of age 20 to 40 years 
women: men ratio 3:1 with a past history easy bruising or 
menometrorrhagia Idiopathic TP 0 mutation of ADAM TS13 gene. 
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Diagnosis 
1. Lab testing for antibodies serological testing is usually not 
useful due to low sensitivity and current testes. (Antinuclear 
antibody non specific) 
2. Peripheral smear shows large platelets otherwise normal 
morphology and Hepato splenomegaly. 
Lab. Inv. 
 HIV hepatitis C, Serum protein electrophoresis, Hypogamma 
globulinemia, IgA deficiency, Monoclonal gammapathies 
Von Willebrand’s disease – Most common  
 Inherited bleeding disorder – occurring in 1: 800: 1000 
individuals.  Heterogenous multimeric plasma glycoprotein. 
J It facilitates platelet adhesions under conditions of high stress. 
J It serves as a carrier of factor VIII anti-hemophilic factor 
J Normal plasma VWF levels > 10 mg/dl 
3 major types VWD 
Type I Milder form hemostasis (50 % activity) 
Type II Less common normal or near normal activity VWF is a 
qualitative defect. 
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Type III Severe form (offspring of both parents usually 
asymptomatic) 
Acquired VWD - Waldenstorm’s macroglobulinemia,  
Wilm’s tumour, Lymphoma 
Von Willebrand’s Disease 
It is defined clinically as disease of women as described in 1926 
by Eric Von Willebrand in his first booklet.  
Diagnosis by  
J Prolonged BT/aPTT 
J Von Willebrand’s factor Ag : assay 
J Von Willebrand’s factor AC 
J Factor VIII assay 
 Prolonged aPTT alone is documented in mild forms prolonged 
aPTT without clinical bleeding in HMWK1, PK1, FXII, FXI, FIX, FVIII 
deficiency 
 Prolonged PT : Factor VII, Vit. K deficiency warfarin 
anticoagulants, Liver disorders. 
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Hemophilia A 
 Factor VIII deficiency is an x linked recessive disorder. Factor 
VIII, a coagulant protein is Synthesized in Liver and circulated. 
Deficiency of < 5 % Factor VIII  is Mild, 5% - 10 %  being moderate 
and  > 10 % is severe disease 
 Hemophiliacs A are male patients.  Carrier hemophiliacs are 
assessed with perioperative factor VIII levels. 
Hemophilia B 
 Factor IX single protein activated to IX A.  Synthesized in liver 
and activated by Vitamin K. 
Factor XI deficiency  
 Factor XI deficiency 160 KDA diamino protein activated to active 
protease inherited as autosomal dominant pattern.  It will present as 
post menopausal or peri operative bleeding. 
 Any patient with prolonged APTT should be evaluated for factor 
IX, VII, XII assays. 
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Menstrual scores with inherited bleeding disorders  
Sl. No. Description PBAC Score 
1 Causes of Hemophilia A 111 
2 Causes of Hemophilia B 115 
3 Von Willebrand’s disease 139 
4 Factor XI deficiency 108 
5 Idiopathic thrombocytopenic purpura 100 
 
 
J VWF Disease has an incidence 1.2 % as per Rodeghiero, 1987 
J Abnormal bleeding and normal pelvic anatomy as per Sharper, 
2004 
J This disorder more common is in Caucasian than in African or 
in as per American Women Miller, 2003. 
J VWD accounts for Menorrhagia in 60-70%of the cases as per 
Kadir, 1998 
J According to ACOG 2001, needs ristocein cofactor VWF and CO 
for diagnosis. 
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J VWF related menorrhagia (Elnasher, 2007), Kabir 2004 says 
endometrial ablation for VWF. 
In a survey 99 cases from hemophilia society in UK, 78 % of 
type I Von Willebrand’s disease, had heavy menstrual periods.71 % 
required medical attentions 15 % required hysterectomy. Ragini et al., 
93 % of 38 women with Von Willebrand’s disease suffered from heavy 
menstruation. 53 % of them have prolonged periods since menarche. 
Mauser Bunschoten et al.,says Subjective menorrhagia is reported. 
Foster et al., (1995) 23 % of Von Willebrand’s disease type 2 and type 
3 had hysterectomy. NSAIDS are avoided in bleeding disorder because 
it will affect the coagulation profile. 
New York Study 
 Type I Von WIllebrand’s disease (Midcycle pains) (Mittleschmerz) 
has been experienced because of subsequent haemorrhage into 
corpus Luteum and peritoneal irritation due to bleeding edges. 
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 Prevalence of merrorrhagia in Von Willebrand’s disease 
Sl. 
No. 
Author Number of Study Prevalence 
1 Ediund et al., 30 20 % 
2 Kadir et al., 150 13 % 
3 Dilley et al., 121 7 % or all 
16 % in Caucasians 
4 Woo et al., 38 13 % 
TOTAL 339 10.9 % 
 RCOG 1999, guidelines for the AUB, recommends that those 
who have bleeding disorders should have a coagulation profile done 
(Recommendation Grade C). 
 2001 ACOG guideline screening for Von Willebrand’s disease 
should be done in all adolescents with menorrhagia as well as adults 
with no pelvic pathology and in all women prior to hysterectomy. 
 Dilley et al., says 50 % Von Willebrand’s disease clinically 
presents as menorrhagia.   4 % had factor IX deficiency. 
 Philip et al., abnormal platelet aggregates and decreased 
platelet ATP release.  47 % of patient with menorrhagia.  One 
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diagnosed thrombocytopenia most common cause of adolescent 
menorrhagia.  13 % incidence in 10-19 years. 
Diagnosis of bleeding disorder is essential 
J It enhances rapid and effective treatment of cases. 
J If surgical interventions are necessary, the risk of bleeding 
disorders and complications can be minimized and morbidity 
decreases. 
J Genetic clarifications and important implications management 
and prenatal diagnosis. 
Chronic endometritis  [AUB-E] 
J Histological diagnosis by findings of plasma cells in the 
endometrial stroma. 
J Causes – Chlamydia, tuberculosis, mycoplasma, IUCD induced, 
foreign body induced, radiation exposure. 
J Varied, presentations inter menstural bleeding, post coital 
bleedings, and menorrhagia  
J Clinical presentation is normal except for the pain on motion of 
cervix, uterine tenderness and chronic pelvic pain 
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J Direct and indirect causes inflammatory cells release proteolytic 
enzymes that damage subepithelial capillary plexus and surface 
epithelium rendering fragile and prone to erosions. 
Genital Tuberculosis :  Female genital tuberculosis first 
described by Morgagni in 1744 on autopsy of young lady. Incidence 
1-197 (Varies from place to place).  All India Institute of medical 
sciences 16 % prevalence,  42.5 % present with infertility. 
Mycobacterium Tuberculosis is usually secondary to pulmonary 
tuberculosis, primary site of primary genital tuberculosis is cervix and 
vulva spread by direct, hematogenous and lymphatic route.  It 
involves fallopian tubes 90-100 %, endometrium 50-80 %, ovaries 20-
30 %, cervix 5-15 %, rarely vulva and vagina 1 %. Apart from fever 
with night sweats Anorexia, weight loss, poor general conditions. 
Menstural disturbances like menorrhagia, puberty, menorrhagia, 
amenorrhoea, PMB, hypo and  oligomenorrhoea, lump abdomen, 
ascitis, pleural effusion, acute pain abdomen, abnormal vaginal 
discharge. 
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Diagnosis 
1. CBC   Non specific 
2. Chest x-ray  Confirm, coexisting respirator y TB 
3. Mantoux  55 % sensitivity, 80 % specificity 
4. Serological test – monoclonal, antibody based ELISA by 
sandwitch technique. 
5. Endometrial biopsy - TB endometritis diagnosed 13.6 % mostly 
diagnosed by presence of focal, collection of lymphocytes with or 
without presence of dilated glands and destruction of 
epithelium. 
6. Mycobacterium, smear and culture diagnosed by Lowenstein 
Jenson medium 51 % and Guinea pig inoculation 11 %. 
7. PCR  :  Rapid sensitive and specific molecular biological method 
detection rate 11-50 %. PCR targets 65 KDA proteins encoding 
gene IS 6110 element and mpt 64 gene. 
8. Imaging Studies 
 Use bilateral solid masses with scattered genital tubercles in 
chronic genital tuberculosis. 
9. CA125 Levels are nonspecific. 
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10. Hystero-salphingography, laproscopy, showing blocked fallopian 
tubes, peritonitis, periovarian adhesions. Bowel adhesions, fitz-
hugh cutis syndrome. 
 Sudherland, tuberculosis patients  shows 10/1000 patients had 
AUB 
 Roy et al., shows AUB in 246 patients occurring in 15-60 
years 
Age distribution 
Shaefer et al.,   80-90 % Between 20-40 years 
Sudherland et al.,  704 patients at 20 years 
In India   68-89 % Between 20-30 years 
Sl. 
No. 
Particulars No. of 
Patient 
< 20 20-30 
years 
30-40 
years 
> 40 
years 
1 Gupta et al. 47 13 68 19 0 
2 Devi 144 12 70 4 0 
3 Hafez and 
Tandon 
120 33 89 6 1 % 
4 Chhabra et al. 57 17 74.2 5.6 1.55 
5 Rattan et al., 50 0 76 24 0 
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Sl. 
No. 
Particulars No. of 
Patients 
Culture 
+ ve 
HPE 
+ve 
Both 
1 Chhabra et al., 150 6 6.1 1.3 
2 Star et al., 118 7 46 NA 
3 Roy et al., 800 10.9 9.8 11.8 
4 Gupta et al., 40 2.5 2.5 2.5 
 
Incidence of Tuberculosis by Laparoscopy 
Sl. 
No. 
Particulars No. of Cases No. of TB 
confirmed by 
Laparoscopy 
1 Krishna et al., 697 10.3 
2 Deshmuk et al., 500 9 
3 Merchat et al., 687 14.1 
4 Gupta et al., 150 26.7 
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Sl. 
No. 
Particulars   
1 Shafer et al., TB Endometrium 50-80 % 
2 Norgales Ortiz et 
al., 
TB Endometrium 60-70 % 
3 Oosthuian et al., TB Endometrium 16 % 
4 Bazoz Mallika et 
al., 
TB Endometrium Demonstrate discrete 
granulomas 
5 Booma Williams  Focal collection of 
Lymphocyte in 
endometrium 
Iatrogenic Causes of AuB 
 Drug induced mostly steroids, progesterone, pure estrogen, 
depot injections, progesterone only pill, combined pill, TCA, SSI. 
Drugs used with enzymatic stimulants such as cimetidine, ranitidine, 
rifampicin, griseofulvin and smokers.  Anticoagulants warfarin, 
heparin not included.  It is included in [AuB-C] 
Estrogen withdrawal bleeding 
1. Bleeding following bilateral oophorectomy 
2. Breakthrough bleeding with estrogen only pills 
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Estrogen break through bleeding 
1. Relatively low levels of chronic estrogen typically result in 
intermittent spotting or staining that is generally light  in 
volume. 
2. Relatively high levels of chronic estrogen typically result in long 
period of amenorrhoea followed by profuse periods of varying 
durations. 
Progesterone withdrawal bleeding - Similar to normal menstruation 
Progesterone Breakthrough Bleeding (BTB) 
 More common whether estrogen progesterone ratio is very high, 
unscheduled bleeding is used, erratic use of transdermal 
patches, vaginal rings. 
  Levonorgesterol– Intra uterine system – spotting is more 
common in 3-6 months.  In a UK study lot of new uses ceased by the 
end of the first year because of bleeding complaints. In Brazilian study 
25 % complaints of vaginal suppository in first 6 months of usage. 
Systemic causes of agents that interfere with dopamine metabolism 
have the potential to cause AUB secondary to disorders of ovulation.  
Tricyclic Antidepressants and Phenothiazines belong to group of drugs 
that impact dopamine metabolism by reducing serotonin uptake.  It is 
thought that the resulting reduced inhibitors of prolactin release 
causes prolactin related disruption is the HPO axis. 
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Ovulatory Dysfunction 
 Endocrine abnormalities like hypothyroidism, hyperthyroidism, 
eating disorders like bulimea nervosa and anorexia nervosa.  Exercise 
induce amenorrhoea, severe stress induced anovulation. 
Eating Disorders 
 Hypothalamic dysfunction is severe in anorexia and may affect 
the HPO axis in addition to reproductive axis.  
 Exercise induced anovulation – notable variation in anovulation 
cyclic interval, length due to reduced hormonal function and 
shortened luteal cycles.  There is a definite correlation between body 
fat and reproductive function.  (Billewicz, 1976, Johnson 1975, 
Abraham 1982). 
 Stress induced anovulation increase in CRH causes variable 
pulsatile release of GNRH. 
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Anorexia nervosa     Stress 
Bulimia        Intense 
exercise 
Leptin     CRH ↑ 
▲    Insulin glucagon &  Cortisol ↑   Opiods 
 Catecholamines 
 
    ▲ Pulsatile GnRH 
Hunger  ↑ NPY 
 Neuropeptide Y  ▲  fSH & LH Levels 
 
   Anovulation / amenorrhoea  
PCOS 
 Incidence 4-12 % causes of ovulation dysfunction. 
ESHRE / ASRM (Rotterdom 2003) 
 To include two out of the three  
1. chronic-oligo / anovulation 
2. Clinical and biochemical signs and symptoms of hyper 
androgenemia polycystic ovaries with exclusion of related hyper 
androgenic disorders 
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AE – PCOs (2009) 
1.  Hyper androgenism hirsutisim and hyper androgenemia 
2. Oligo / anovulation (PCOs) 
3. Exclusion of other androgen related disorders 
Variable range of menstrual irregularities from amenorrhoea to 
menorrhagia 
Treatment 
Observation : Fairly regular cycles  6-8 cycles per year with mild 
hyperandrogenism should be periodically screened for dyslipidemias 
and diabetes mellitus. 
Weight loss, exercise, dietary modification and regularisation of 
cycles with OC pills. 
Insulin Sensitizing agents like metformin not FDA approved category 
B drug can be used for ovulation induction.  It reduces 
androgen level in lean and obese PCOS  (Batukon 2001, Essan 
2006, Hass 2003).  Hirsutism and acne are managed 
symptomatically. 
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Thyroid Disorders 
 Thyroid hormones and thyroid stimulating hormones produce 
varying ranges of menstrual problems because of molecular mimicracy 
of TSH and LH and FSH according to Spill over theory.  
Common Causes of Hypothyroidism are  
1. Primary autoimmune Hypothyroidism, Hashimoto’s thyroiditis, 
atrophic thyroiditis 
2. Iatrogenic – subtotal thyroidectomy, external irradiation 
3. Drug induced – Lithium, amiodarone 
4. Congenital disorders 
5. Infiltrative disorders, amyloidosis, sarcoidosis, 
hemochromatosis, scleroderma, cystinosis, riedel’s thyroiditis. 
Common causes of Hyperthyroidism are 
1. Primary Hyperthyroidism – graves disease, toxic nodular goiter, 
toxic adenoma, silent subacute thyroiditis, ingestion of excess 
hormone, thyroid hormone secreting tumours. 
 Coagulation and fibrinolytic abnormalities associated with 
thyroid dysfunction as per J Clin Endocrinol Metab, 2007 
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General 
Hemostatic 
tests 
Hypo Hyper Sub.Hypo Sub.Hyper 
General 
hemostatic tests 
↑ ↓ =  
Bleeding time ↑  =  
aPTT ↑  =  
PT ↑  =  
Clotting time ↑    
Prothrombin 
fragment 1-2 
 =   
 
Hypothyroidism and Hyperprolactinemia 
  Classically hypothyroidism causes amenorrhoea, 
hyperthyroiditis causes menorrhagia. 
Thyroid hormone 
TRH   Prolactin   Dopamine 
ISH      4 Pulsatile GN2H 
      4 LH and FSH 
Anovulation & 
amenorrhoea 
Varied response 
 TRH increases, TSH by pituitary gland, lactotropes, increasing, 
prolactin secretors.  A circulating increases in prolactin results is a 
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compensatory increase in central dopamine the primary inhibitor of 
prolactin secreted. 
 Increasing central dopamine levels alters GnRH secretion 
thereby disrupting normal cycle gonadotropic secretor and preventing 
ovulation. 
J Poorly understood results thyroid receptors are found as most 
cases. 
J Increases sex hormone binding globulin levels. 
J Altered levels of unbound active sex steroids 
J Prolactin receptors are found in endometrium and ovary. 
Correction of hypothyroidism correct hyper prolactinemia if the 
symptoms persist needs for the evaluation. 
J Both hyperthyroidism and hypothyroidism menstrual disorders 
amenorrhoea to menorrhagia [Koutras 1997]. 
J Thyroid dysfunctions – menstrual abnormalities antedate other 
clinical findings [Joshi 1993]. 
J Hyperthyrodism causes amenorrhoea, hypomenorrhoea, 
menorrhagia 5 % 
J Treating unduly and hypothyroidism usually corrects bleeding 
dysfunction [Krarsar 1999, Wilansky 1989]. 
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Investigations  
1. In true anovulatory bleeding the menstrual history alone can 
establish the diagnosis with sufficient confidence that treatment 
can begin without additional lab investigations 
1. Complete  Blood count 
 Hb%   RBC in million 
 PCV, ESR  Platelet count 
 
2. Bleeding time - Evaluating platelet function 
 Clotting time - Clotting factor 
3. Prothrombin time - Extrinsic and final common pathway  
factor 
4. APTT   - Activated Partial thromboplastin  
Involves Intrinsic and final common 
pathway factors. 
Investigations of coagulation profile (Level II) 
 PT and aPTT – Low positive and high negative predictive value. 
 Von Willebrand factor, ristocetin cofactor activity. 
 Factor VIII levels, Blood grouping, typing 
 PTA – Platelet function analyser is having 100 % sensitivity and 
specificity and is less invasive. 
 47
Closure Time PFA 100 
 
 
 Liver function tests – all clotting factors are synthesized in Liver. 
 Renal function tests- erythropoietin of kidney is the one of the 
stimulants for erythropoiesis. 
 Ultrasonogram – Diagnosis of structural cases, polyp 
myohyperplasia. 
 If uterus is enlarged 10-12 weeks USG is definite. 
[Recommendations Level II] 
X-ray chest PA view  - Respiratory tuberculosis 
Mantoux   - For tuberculosis less sensitive 
Cervical culture for Gonococcal / Chlamydia/tuberculosis 
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Endocrine causes 
Fasting prolactin levels 
Thyroid function tests – TSH free T3, T4 
If cycles are regular D3 measurement LH, FSH estradiol. 
Decrease FSH are consistent with secondary ovarian 
dysfunctions because of pituitary and hypothalamus causes. 
Increase FSH and LH ratio; Serum estradiol – Low because of 
decreased ovarian reserve or primary ovarian failure. 
High LH and FSH ratio with secondary sexual characteristics at 
an unusually young age. - Precocious puberty. 
LH/FSH ratio >2:1 or 3:1 diagnostic of PCOs. FSH results can 
decrease with oral contraceptives. 
 Androgen excess can be demonstrated by measuring total and 
free testosterone levels.  An elevated free testosterone level is an 
indicator of androgen excess. Endocrine investigations are 
unnecessary, unless there is clinical – suspicious of thyroid diseases / 
premature ovarian failure (Level II). 
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Evaluation of Endometrium 
 RCOG current guidelines to TVS should be for initial 
investigation with hysteroscopy, backup (LEVEL Ib). 
ACOG practice Bulletin No.142 
 There is distinct increase in the incidence of endometrial 
carcinoma from 30-34 years.AS ON  2.3/19000 in 1995 to age 34-39 
(6.1/100000). Age > 35 needs endometrial evaluation.  Women < 35 
who have sufficient risk factors, morbid obesity, PCOs, needs 
evaluation Storall’s study, pipelle’s endometrial sampling says  97.5 % 
of endometrial surface in AUB cases.  Guido colleagues study says  97 
% Causes are evaluated. The possible explanation is of limited usage. 
Pipelle endometrial sampling samples 5 % surface areas. 
Saline sonohysteroscopy (Level IB evidence) 
Office – Hysteroscopy for better diagnostic accuracy of their 
diagnosis of structural causes.  Timing of sono hysteroscopy.  Women 
et al., sap. False positive rate 17 % done on Day 16 – Day 28.  In 
patients with irregular  periods of an empirical course of progesterone 
long day 10-14 days as a medical   curretage and time the ultrasound. 
Evaluations to the withdrawal bleed may be appropriate MRI. 
Differentiating size, number locations of fibroids extending into cavity 
and carcinomatous changes.  Dilatation and curretage has no 
advantage over clinic based techniques (Level Ib) evidence. 
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Endometrial, histology, anovulatory cycles and chronic endometritis. 
Endometrial culture – modified  petroff method by Lowenstein jensons 
medium. 
Therapy 
 Pharmacological therapy and Surgical therapy 
Pharmacological Therapy 
 Anti fibrinolytic agents  Tranexemic acid 
 Anti prostaglandins   mefenemic acid 
 Hormonal therapy  Norethisterone, intra uterine,  
progestagens, OC pills, Danazol, 
GNRH analogues, gestrinone, 
tamoxifen 
 
1. Antifibrinolytics – TDA approved – Tranexemic acid  
 Reversibly blocking lysine binding sites of plasminogen. 
 Preventing, plasmin and fibrin polymer interlocking.  Resulting 
in fibrin degradations, stabilizing clots, reducing bleeding. 
 Tranexamic acid is cautiously used in thrombembolism.  TA is 
used in BMB is DMPA.  IUCD induced menorrhagia.  TDA has 
approved 1300 mg. 3 times a day for 5 days, oral availability of 
35 %. 
2. Anti Prostaglandins – mefenemic acid decrease – endometrial 
prostagladins cox inhibitor – decreased blood loss by 25 % 
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including symptoms of dysmenorrhoea, headache, nausea, 
diarrhoea, depression. 
Medical Treatment 
NSAIDS in menorrhagia (nakarainen 1986 b, Marchini 1995) 
 Conventional NSAIDS non specifically inhibit  COX ENZYMES 
 CO X inhibitors is associated with  both results but not  proven 
now (Hayer, 2002). 
 COX inhibitior usage also causes increased myocardial 
infarction stroke and heart failure.  (Solmon 2005). 
Oral Progestogen 
 Progestine halt endometrial growth and allows an organized 
sloughing with their withdrawal (Sarrikoski, 1990). 
Hormonal Therapy 
 Systemic progesterone and medroxy progesterone  in an- 
ovulatory bleeding. 
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ACOG guidelines  
 First line management combined OCpills  
 Levonorgesterol IUD – 2nd choice 
Combined OCpills  
 To Correct menstrual irregularities and correct anovulation 
reduces blood loss by 80 % extended release cycle tablets or 
continuous OCpills 20 µg ethinyl estradiol and 100 µg Levonorgesterol 
either 84/7 shortens hormone free interval (Level 1b) evidence. 
Levonorgesterol reduces by blood loss in 74-97 % (Singh 2005, 
Steward 2007) 
Dilatation curettage rarely used for treatment because its effect 
are temporary.  D/C is used to arrest refractive bleeding To high dose 
estrogen. (ACOG 2000, Stabinsky and Associate, 1999). 
 Extended cycle OCpills usage or depot medroxy progesterone 
are the causes of menorrhagia according toACOG 2009b. 
Danozol 
 Synthetic antiandrogenic with antiestrogenic and anti 
progesterogenic activity.  It inhibits the release of pitutary 
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gonadotropins direct suppressive effect on endometrium.  It is used as 
an    preop adjuvant management .  
Gestrinone / Tamoxifen 
 Control blood loss by pituitary down regulation and subsequent 
reduction in the cyclic ovarian activity. 
Management of Coagulation Abnormalities 
1 Tranexemic acid shepherd randomized trials approves 54 % 
reduction in blood loss. 
2. Combined OCpills Inhibit endometrial growth as well as 
increasing fVIIIC and VWF.AC levels. As per  Foster et al., 
standard dose of OCpills provides 24 % reduction in blood loss 
in most women . 
3. DDAVP (Desmopressin Nasal Spray it causes 
thrombocytopenia. 
 Levonorgesterol IUCD – 20 µg L Levonorgesterol eluting in every 
24 hours lasting for 5 years.  Main problem is high discontinuation 
rate 20 % (Stewart et al.,) and no effect on fVIII levels. 
 LNS (IUS) more effective in the management  with statistically 
significant less treatment failure (11 % to 36 %) 
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Cochrane Review 
 Cyclical progesterone from day 15 to day 26 offers no advantage 
over other drugs.  
 Instead 21 day progesterone therapy taken from day 5 to day 26 
should be recommended because it causes significant blood loss (Level 
1B evidence). 
Medical Treatment 
NSAIDS in menorrhagia (nakarainen 1986 b, Marchini 1995) 
 Conventional NSAIDS non specifically inhibit both 
cyclooxygenase Cox2 
 COx2 inhibitors is associated with both results but not proven 
neither (Hayer, 2002). 
 COx2 inhibition usage also causes increased mycordial  infact 
stroke and heart  failure.  (Solmon 2005). 
Oral Progestogens 
 Progestine halts endometrial growth and allows an organize of 
sloughing with their withdrawal (Sarrikoski, 1990). 
 Ovulatory menorrhagia is relatively on unresponsive to cyclic 
administration of progestines (Cameron 1987, 1990, Preston 1995, 
Singh 2005). 
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 Prolonged use of high dose progestins is often associated with 
side effect such as mood changes, weight gain, bloating, headaches, 
atherogenic changes in lipid profile (Lethaby 1998b). 
 Combined OCpills – hormonal contraceptives are effective.  It 
causes diminished prostaglandin synthesis and decreased 
endometrial fibrinolysis (Irvine 1999). 
Androgen 
 Menstrual loss is reduced into half.  It may induce amenorrhoea 
(Beumount 2002, Chimbra 1980, Higham 1993). 
 In The heavy menstrual bleeding suggested dosing of 100-200 
mg taken orally everyday (Chimbra 1980b). 
 The drug is reserved as a second line of choice prior to surgery. 
(Banger 2004). 
Von Willebrand Disease 
 Dilatation and curettage worsens Von Willebrand’s disease 
(James 2009a). Hysterectomy is curative in VWD. Consultation with 
haemotologists with perioperative desmopressin and factor 
concentrate administration according to ACOG 9b. 
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Surgical Methods 
Endometrial ablation 
 Minimal invasive surgical methods currently 5  FDA approved 
for the management of abnormal uterine bleeding . 
MEAS (Microwave Endometrial Abalation System) Novasure, 
Thermochoice, Heroption, hydrothermablator (Level II evidence) 
  Criteria  for management Maximum uterine length by sounding 
of 10 cms except MEAS which is 14 cms. Novausre, MEAS, 
thermochoice licensed for abalation of uterine cavity with less than 3 
cm fibroid. Absolute contra indication of procedure are malignancy 
infection, uterine perforation. Endometrial ablative procedure (ACOG 
2007) recommends endometrial sampling before endometrial ablation. 
SAFETY and EFFICACY REGISTRAR of NEW INTERVENTIONAL 
PROCEDURE (SERNIP A, B, C1C2, D) 
 Only MEAS and Thermochoice are certified in category B 
 Long term satisfaction in patients  is high with hystrectomy but 
associated with morbidity and mortality should be offered also safe 
alternative wuth (Level IV evidence). Laproscopic AVH is more 
expensive than the abdominal hysterectomy and carries less 
complication in experienced hands as per (Level 1B evidence) 
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AIM OF THE STUDY 
1.  To conduct in depth analysis of non structural causes of 
abnormal uterine bleeding   
2. To find the incidence of non structural causes of  AUB with 
special emphasis on careful history taking and clinical 
examination and inclusion of simple test to diagnose hemostatic 
disorders. 
3. To find out relations between age and symptoms  
4. To find out the  MORBIDITY PARAMETERS OF of non structural 
causes of  AUB 
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MATERIALS AND METHODS 
This is a prospective study conducted in Mahatma Gandhi 
Memorial Hospital, Trichy during period of June 2011-May 2012.   
INCLUSION CRITERIA  
• Age between 13-55 yrs  
• With clinical sign and symptoms of  AUB. 
EXCLUSION CRITERIA 
• Ultra sonically diagnosed structural causes of  AUB from the 
patients with age of 13-55 yrs  
METHODS 
1. History  
2. Clinical assessment  
3. Complete blood count  
4. Hb% by sahli hemoglobinometer normal value is 11-14gms% 
5. Packed cell volume -28-32% 
6. TC      DC      P L E  
7. RBC VALUE IN – 5-6 millions/cumm  
8. PERIPHERAL SMEAR – leishman stain and geimsa stain by oil 
immersion method [for 10 hpf] 
9. RBC VALUE IN – 5-6 millions /cu mm 
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10. Thyroid function test – TSH-.44-.345 MIU /ML T-3 LEVELS-.49-
2.02NG/ML T-4 VALUE  MICRO GRAM/DL 
11. LIVER FUNCTION TESTS – as per lab values  
12. BLEEDING TIME blotting paper method -2-3 min  
13. Clotting time –tube method 3-5 min  
14. PROTHROMBIN TIME & ACTIVATED PARTIAL PROTHROMBIN 
TIME  by siemens thromborel kit  
17. FACTOR 8 AND 9 LEVELS AS PER KIT . 
18. SPUTUM FOR  ACID FAST BACILLUS  by ziehl nielson 
technique  
19. X-ray chest PA view 
20. USG TO R/O  Structural Causes  
21. ENDOMETRIAL BIOPSY  by pipelles endometrial currete in 
indicated cases. 
22. Endometrial culture in possible cases in lowenstein jensen 
medium specimen concentrated by modified petroff method 
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RESULTS 
 
Pie Diagram showing Incidence of AuB
40
100
Incidence of AuB Total Cases
 
Incidence of AuB 
 40 % correlates with the world records. 
Overall incidence correlates with various records of 10 to 30 %. 
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RESULTS AND OBSERVATION 
 
Incidence of AuB of 1 year 
Month 2011 
June 
2011 
July 
2011 
August 
2011 
Sep 
2011 
Oct 
2011 
Nov 
2011 
Dec 
2012 
Jan 
2012 
Feb 
2012 
Mar 
2012 
Apr 
2012 
May 
Total 
Total 
Cases 
200 186 186 226 235 206 196 197 140 170 190 186 2318 
Percentage 40 42 35 39 42 45 36 40 42 39 38 40 39.33 
 
 Bar Diagram showing the Incidence of AuB of 1 year 
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Incidence of Coagulation Disorders 
Sl. No. Description No of Cases 
1 ITP 9 
2 Thrombocytopenia with 
Splenomegaly 
7 
3 Prothrombin time 
prolongation 
3 
4 Prothrombin time activated 
and prothrombin time 
prolongation 
6 
TOTAL 25 
 
Incidence 12.5 % 
Incidence by  Kadir et al.,  13 % 
   Dilley et al.,  7 % 
   Woo et al.,  13 % 
   Ediun et al., 20 % 
My study correlates with the result.
  
Incidence of Coagulation disorders 
Total 25 Cases   :  Incidence 12.5 % 
 
9
7
3
6
ITP Thrombocytopenia with spleenomegaly Prothrombin Time Prolongation PT/APTT Prolonged
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AuB(E) Endometrial Causes 
Sl. No. Description No of Cases 
1 Chronic non specific 
endometritis 
12 
2 Tuberculosis endometritis 
culture +ve 
3 
3 Genital tuberculosis by 
ultrasound ascitis and pleural 
effusion 
5 
TOTAL 20 
 
Incidence 10 % 
Oosthuian et al., of TB Endometrium of 16% and  
Chhabra et al., shows the incidence of TB culture +ve as 1.3 % ,  
Gupta et al., shows the culture +ve of 2.5 %  
coincidence with my study. 
 
 
 
  
AuB(E) Endometrial Causes 
Total 20 Cases   :  Incidence 10 % 
12
3
5
Chronic non-specific endometritis
Tuberculous endometritis culture positive
Genital Tuberculosis by ultrasound ascitis and pleural effusion
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AuB(O) Ovulatory Dysfunction 
Sl. No. Description No of Cases 
1 Subclinical hypothyroidism 5 
2 Hyperthyroidism 10 
3 Hypothyroidism 45 
TOTAL 60 
 
Incidence 30 % 
Koutras 1997, shows an incidence of 30 – 40 % of patients with 
menstrual irregularities with thyroid dysfunction. 
Wilansky Krasur and Josh et al., shows an average incidence of 
25-50%. 
AuB(O) Ovulatory Dysfunction 
Total 60 Cases   :  Incidence 30 % 
 
5
10
45
Subclinical hypothyroidism Hyperthyroidism Hypothyroidism
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Symptoms of Coagulopathies 
Sl. 
No. 
Description Oligo / 
hypo  
Amenorrhoea Menorrhagia P 
value 
1 ITP 0 0 7 0.011 
2 Thrombocytopenia 
with splenomegaly 
0 7 7 0.936 
3 PT prolonged  0 0 3 0.781 
4 PT/aPTT 
prolonged 
0 0 6 0.053 
 
ITP and PT/aPTT prolonged with probable coagulopathy have a 
significant p value with the symptoms. 
Symptoms of Coagulopathies 
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Symptoms of AUB(E) and AUB(O) 
Sl. 
No. 
Description Oligo / 
hypo  
Amenorrhoea Menorrhagia P 
value 
1 Chronic 
Endometritis 
0 12 12 0.487 
2 TB Culture 0 1 2 0.216 
3 TB Ascitis with 
pleural effusion 
5 5 0 0.109 
4 Subclinical 
hypothyroidism 
0 0 5 0.004 
5 Hypothyroidism 18 18 27 0.054 
6 Hyperthyroidism 1 1 8 0.008 
 
Subclinical hypo thyroidism and hypothyroidism have a 
significant p value of 0.004 and 0.054 respectively. 
 
Symptoms of AuB(E) and AuB(O) 
0
12 12
0
1
2
5 5
0 0 0
5
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0
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Chronic
Endometritis
TB Ascitis with
pleural effusion
Hypothyroidism
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Correlative study of symptoms 
 Pts with 
coagulation 
abnormality 
N=25 
Pts without 
coagulation 
abnormality 
N=80 
P value 
Age since 
menarche >24 
months 
16 (64) 8 (10) 0.000 
Since menarche 
< 24 months\ 
4  (16) 20 (25) 0.040 
Family History 
of Bleeding 
disorder 
6 (24) 6 (7.5) 0.480 
History of 
Bleeding 
Symptoms 
12 (48) 5(6.25) 0.001 
Post operative 
bleeding 
12 (48) 6 (7.5) 0.000 
Postpartum 
bleeding 
18 (72) 12(15) 0.001 
 
Patients with symptoms since menarche more than 24 months 
and post operative bleeding have a highly significant p value of 0.000. 
History with bleeding symptoms and postpartum bleeding have 
a significant p value of 0.001. 
Correlative Study with Symptoms 
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Correlation of Age with Symptoms 
 
 Respondents Percent 
Below 20 50 25.00 
20 – 30 09 04.5 
30 – 40 41 20.5 
40 – 50 79 39.5 
Above 50 21 11.4 
Total 200 100 
 
 Symptoms predominates with an average age group of 40-50 
accounting for 39.5 cases. 
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Patients with Oligomenorrhoea 
 Respondents Percent 
Plus 110 55.0 
Minus 90 45.0 
Total 200 100.0 
 
Patients with oligomenorrhoea predominates accounting for 
55 %. 
Patients with Oligomenorrhoea 
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Patients with menorrhagia 
 Respondents Percent 
Plus 160 80.0 
Minus 40 20.0 
Total 200 100.0 
 
 Menorrhagia accounts for 80 % accounting the clinic attetants 
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Age distribution of Coagulation disorders 
Sl. No. Age Group Respondents 
1 10 -20 19 
2 20-30 1 
3 30-40 5 
TOTAL 25 
 
 The age group with coagulation disorders predominately 
symptomatic in the earlier age itself. 
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Age distribution of Chronic endometritis 
Sl. No Age group Respondents 
1 10 -20 1 
2 20-30 0 
3 30-40 1 
4 40-50 18 
5 Above 50 0 
TOTAL 20 
 Disease predominately involves in the age group of 40-50. 
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Age distribution of Ovulatory Dysfunction 
Sl. No Age group Respondents 
1 20-30 0 
2 30-40 4 
3 40-50 42 
4 Above 50 14 
TOTAL 60 
 
 Symptoms predominates with the age group of 40-50. 
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Association of BMI and Symptoms 
Sl. 
No. 
BMI  Hypo 
menorrhea 
Amenorrhoea Menorrhagia 
1 18-25 166 45 16 83 
2 < 18 1 0 1 1 
3 25-29.9 33 25 20 27 
 
 Definite increase in the incidence of menorrhagia with 
increasing BMI. 
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Association of Anemia with Symptoms 
Hemoglobin 
Level 
Pts with 
coagulation 
abnormality 
N=25 
Pts without 
coagulation 
abnormality 
N=80 
P value 
<6 g/dL 4 (16) 2(2.5) 0.001 
6 -10  g/dL 19 (76) 50 (62.5) 0.287 
10 > g/dL 2 (8) 18 (22.5) 0.061 
 
 Hb less than 6 grams have a significant p value of 0.001. 
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 Out of 200 patients examined between 13 years and 55 years 
from June 2011 to May 2012 by careful history taking, clinical 
examination, investigations including sonography, endometrial 
histology and number of patients taking anticoagulants and oral 
contraceptive pills, hormones, and NSAIDs. 
 Patients are subjected to complete blood count, platelet count, 
bleeding time, clotting time, prothrombin time, activated partial 
thromboplastin time. 
 Results are statistically analysed. 
 Incidence of non-structural causes of 52.5 % in 200 cases and 
large amount of cases are not identified because of the lack of facilities 
to determine the factor assay and hormone assays as they are cost 
effective.  By increasing the diagnostic modalities patients in the 
AuB (N) category will be categorized in that particular groups. 
 Incidence of coagulation abnormalities accounts for 12.5 % 
including 3 patients with prolonged prothrombin time in patients with 
warfarin overusage in the treatment of DVT. 
 Incidence of endometritis as low as 10 % because most of the 
cases subsides with antibiotics and they go unnoticed. 
 Incidence of detectable ovulation dysfunction is 30 % in thyroid 
disorders, thyroid dysfunction modifies the balance between the 
coagulation and the fibrinolytic system, coagulation test revealed 
hypocoagulable state in hypothyroidism and hypercoagulable state in 
hyperthyroidism. 
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DISCUSSION 
I. Coagulation Disorders 
1. Regarding the incidental studies  
 Ediund et al., Dilley et al., and Woo et al., have the incidence of 
20 %, 13 % and 30 % respectively. 
 Trasi et al., and Kadir et al., accounts for 19.16 % and 17%.  My 
study shows 12.5 %. 
2. Menorrhagia since menarche 16 (64 %) patients had the 
symptoms with the significantly higher p value of <0.000 in 
patients with hemostatic disorders similarly noted by  Kadir et 
al., in 53.1 % and Ragini et al., 65 %. 
3. Frequency of bleeding symptoms bruising and bleeding from 
gums have a significant p value of 0.001.  Similar findings are 
revealed from the same p value of post-operative bleeding and 
postpartum bleeding with the p values of 0.000 and 0.001. 
Four parameters that were statistically significant are 
menorrhagia since menarche, history of bleeding symptoms, 
post-operative bleeding, postpartum bleeding and haemoglobin 
level <6g. 
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II. AUB(E) 
 Regarding AUB(E) Chronic endometritis had a p value of 0.487 
for TB culture with p value of 0.216 and for TB ascitis and 
pleural effusion has a p value of 0.109.  Endometritis patients 
usually subsides with antibiotic and the association of uterine 
bleeding is usually less. 
III. Thyroid dysfunction. 
 In the examination of 200 patients 45 patients had 
hypothyroidism and 5 patients had subclinical hypothyroidism 
and 10 patients have hyperthyroidism. 
 Scot and Mussey observed menstrual irregularities in 56 % of 
hypothyroid patients.  Menorrhagia and metrorrhagia alone are 
combined abnormal pattern seen in 75 % 
 Joshi et al., says 45 % increased incidence of AuB in thyroid 
dysfunction patients and 44 % of patients are apparently 
Euthyroid. 
 Wilansky et al., shows the prevalence of 22 % in early 
hypothyroid patients.  Out patients shows that there is a 
definite 30 % incidence of menstrual irregularities with the 
significant p value of 0.05 for hypothyroidism and 0.004 for 
subclinical hypothyroidism and 0.008 for hyperthyroidism. 
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 I conclude menstrual irregularities are significantly more 
frequent in patients with thyroid dysfunction and may preclude 
thyroid dysfunction also prompt investigations of TSH, T3, T4 is 
definitely warranted. 
  
 
 
SUMMARY 
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SUMMARY 
 
1. During the one year study May 2011 to June 2012 of 2318 
patients of which an average of 39.33 % had AUB.  
2. Overall incidence of detectable non-structural causes in our 
hospital is 52.5 %. 
3. Definite increase in incidence of abnormal uterine bleeding in 
both extremes of age. 
4. Incidence of identifiable coagulation abnormalities is 12.5 %. 
5. Incidence of endometrial causes is 10 %. 
6. Incidence of detectable ovulation dysfunction is 30 %.  There is 
a definite association of menstrual irregularities with the thyroid 
dysfunction irrespective of age factor. 
 
  
 
 
CONCLUSION 
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CONCLUSION 
 
 Considering the abnormal menstrual bleeding which is the most 
common complaint that the reproductive age group women bring to 
the physicians, all clinicians who provide the primary care for the 
women must have an organized logical approach to the evaluation and 
treatment of the problem.  
 Careful history taking algorithmic approach of investigations 
rules out non-structural causes.  In a considerable amount of patients 
and avoids unnecessary hysterectomy. 
 Evaluation of patients with the abnormal uterine bleeding is an 
art of the clinician in getting the diagnosis with simple reliable tests. 
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ANNEXURES 
• Proforma 
• Master Table 
Name  : 
 
Age  : 
 
Sex   : 
 
P  L  A    : 
 
IP.NO   : 
 
OP.NO 
 
C/o   : Menorrhagia  Polymenorrhoea  
Metrorrhagia  Oligamenorrhoaea 
Hypomenorrhea Amenorrhoea 
 
H/O  Pres Illness  : Bleeding   Irregular Regular        Absent 
 
Frequency    <21 days 21-35 days       >35 days 
 
Duration    <8 days        2-8 days          <2 days 
 
Volume    >80ml          15-80ml           <15ml  
 
Pads   clots   Pain 
 
Duration of Disease : 
 
Fever/ Loss of weight / Loss of apetite/ Gain of weight 
 
Cold intolerance / Heat  
 
Intolerance/ Constipation/ Diarrhoea/ Palpitations 
 
Bleeding gums/ Per Rectum/ Hematomas/ Hemetemesis 
 
Marital H/O     Dyspareunia/ Post coital  Bleeding/ 
Illegal Sexual  contact 
 
Obst H/O  P L A  
 
Criminal Abortions/Sterilisation/Puerperium 
infection/PPH /Blood Transfusion/Parentral 
Fe/Abruption/Periods Established 
 
Past H/O  HT/DM/Epilepsy/Heart Disease/H/O TB/ H/O  
Swelling in neck 
 
Drug H/O  Anti-Hypertensives/ Coagulants/ Convulsants 
/ Ocpills/ATT 
 
Per H/O  Diet/Alcoholic/Smoker 
 
Family H/O  TB in family member/Thromboembolic disease/ TIA 
/ Bleeding disorder in Siblings 
 
O/E   Conscious     Oriented     Afebrile     Dyspnoea+/-  
Anaemia        Jaundice 
 
Pedal odema   Lymph node    Varicosity 
 
Vital                     T                 PR               BP   BMI  
CVS  RS  CNS 
 
Thyroid               Breast            Spine 
 
L/E Inspection  P/A        Shape  Umblicus Distention 
Scars/  
Hernial orfice 
  
All     Quadrants     Moves with Respiration 
 
PALPATION  Soft          Organomegaly Spleen/  
Liver/ Free fluid 
 
PERCUSSION  Over the mass     Shifting Dullness/  
Fluid Thrill 
 
AUSCULTATION  Bowel Sounds/Abnormal Bruit/ AV Fistula 
 
LOCAL EXAMINATION EXT genitalia/ Public Hair/ Pad of fat 
/polyp/Scars 
 
S/E 
 
VAGINA  Polyp        Granulomas        Discharge 
 
CERVIX  Appearance 
 
P/V  Uterus Size/Position/Adnexa 
 
P/R 
 
 INVESTIGATIONS 
 
 
CBC   HB  TC  DC ESR PCV PT RBC 
 
PERIPHERAL    SMEAR  THROID FUNCTION TEST   
 
LFT 
 
BT                      CT  PT  aPTT  FACTOR VIII  
 
FACTOR IX 
 
URINE 
 
MANTOUX                           SPUTUM/AFB X-Ray  CHEST 
 
USG  
 
ENDOMETRIAL CULTURE    ENDOMETRIAL  HPE 
 
  
 
 
 
Sl. No. Name Age IPNO BMI 
Oligo/ 
Hypo 
Amen 
Menor 
ragia 
Hb 
% 
Platelet 
Count 
BT CT PT aPTT USG TSH 
Free 
T3 
Free 
T4 
EM 
Culture 
Endometrial 
Histology 
LFT RFT 
1.  Mariyaye 37 5240 20 + + – 7.2 115000 2 4 11 23 N N N N N N N N 
2.  Chandra 42 6558 24.6 – – + 8.8 100000 2 4 10 23 N 0.50↑ 0.5 0.4 N N N N 
3.  Backiyam 40 6451 22 – + + 8.2 120000 2 5 11 24 N 0.23↓ 3.2↑↑ 4.2↑↑ N N N N 
4.  Sarala Devi 50 6550 27 + + ⊕ 8 100000 1.80 4 10 20 N 0.55↑↑ 0.2↓ 0.3↓ N N N N 
5.  Maharayee 43 6559 25 + – + 8 120000 3 5 15 15 N N N N N Chronic 
Nonspecific 
endometritis 
N N 
6.  Rani 40 6589 26 + + ⊕ 7.5 100000 2 3 15 23 N 0.65↑↑ 0.1↓ 0.2↓ N N N N 
7.  Sumithra 37 4168 25 – – + 7 50000 3 4 25 24 N N N N N N N N 
8.  Kannamal 42 6486 22 + + – 7.5 150000 2 5 11 24 N N N N N N N N 
9.  Renganayagi 40 6579 23 + + – 7.4 150000 2 3 11 25 N N N N N N N N 
10.  Jency 40 6487 24 + – + 8.2 100000 2 5 15 24 N N N N N Chronic 
Nonspecific 
endometritis 
N N 
11.  Sahaya Mary 50 6614 25 + + – 7.3 150000 2 5 10 20 N N N N N N N N 
12.  Uma 47 6446 24.2 + + – 7.1 150000 2 4 10 20 N N N N N N N N 
13.  Valarmathi 52 6774 20 + + ⊕ 8.5 100000 2 5 10 24 N 0.75↑↑ 0.2↓ 0.23↓ N N N N 
14.  Naga Jothii 52 6580 22 + + – 7 120000 2 4 10 20 N N N N N N N N 
15.  Jensi 20 6485 24 – – + 7.2 110000 2 4 11 22 N N N N N N N N 
16.  Sahaya Mary 50 6615 25 + + – 8.2 100000 2 5 12 20 N 0.55↑↑ 0.23↓ 0.24↓ N N N N 
17.  Uma 47 6447 20 + – + 10.7 120000 2 5 11 20 N N N N N Chronic 
Endometric 
N N 
18.  Kalavathy 53 6773 26 + + + 8.6 100000 3 4 12 22 N 0.56↑↑ 0.28↓ 0.24↓ N N N N 
19.  Mariyayee 50 6804 23 – – + 7.6 120000 2 5 10 20 N 0.32 0.20 0.30 N N N N 
20.  Kokila 40 6802 22 + – + 10.8 110000 2 6 10 20 N N N N N Chronic 
Endometric 
N N 
21.  Periyakka 48 6204 21.1 – + + 8.8 120000 2 5 12 22 N 0.245↓ 2.05↑ 40↑ N N N N 
22.  Selvi 50 7150 25 + + – 8 110000 2 4 12 23 N N N N N N N N 
23.  Vellaiyammal 45 7672 26 + + – 8 110000 2 4 10 23 N N N N N N N N 
24.  Chinnamani 35 4711 24 + + + 10 100000 2 4 10 20 N 0.57↑↑ 0.13↓ 0.14↓ N N N N 
25.  Rajalakshmi 44 4879 22 + + – 6.5 100000 2 4 11 15 N N N N N N N N 
26.  Chellammal 50 7882 20 – – + 8.8 120000 2 5 10 22 N 0.55 0.50 0.20 N N N N 
27.  Nagalakshmi 49 7883 21.6 + + – 7 120000 2 5 10 23 N 0.25 0.30 0.40 N N N N 
28.  Sathiya 19 7475 19 – – + 5 50000 10↑ 5 10 22 N N N N N N N N 
29.  Kalaiselvi 39 5091 20 + + – 6 120000 6 5 10 22 N 0.25 0.30 0.40 N N N N 
30.  Rani 19 6588 20 – – + 6 60000 7↑ 5 10 20 N N N N N  N N N 
31.  Dhanalakshmi 43 8147 22 – + + 8.8 120000 2 5 11 22 N 0.30 3.02 20 N N N N 
32.  Mariyammal 40 8480 28 + + + 8.8 110000 2 5 11 22 N 0.56↑↑ 0.20↓ 0.25↓ N N N N 
33.  Kunjammal 46 5167 27 + + + 10.2 110000 2 4 10 23 N 0.57↑↑ 0.20↓ 0.15↓ N N N N 
34.  Thanalakshmi 13 8582 19 – – + 5 120000 2 5 20 26 N N N N N N N N 
35.  Annakamu 16 5781 19 – – + 3.5 115000 2 5 20↑ 27↑ N N N N N N N N 
36.  Meenakshi 50 6120 20 + – + 7 120000 2 5 10↑ 20↑ N N N N N Chro 
Endometritis 
N N 
37.  Sarasu 43 2528 21 + – + 7.2 100000 2 4 11 22 N N N N N N N N 
38.  Aimo 43 8761 26 + + + 10.5 150000 2 4 10 23 N 0.58↑↑ 0.2↓ 0.15↓ N N N N 
39.  Valarmathy 33 8893 25 + – + 8 160000 2 3 10 22 N N N N N N N N 
40.  Sahera Bee 15 8976 22 – – + 4.5 25000 10 4 10 20 N N N N N N N N 
41.  Meena 28 9056 20 + – + 8 100000 2 3 12 23 N N N N N N N N 
42.  Rani 13 8999 25 – – + 4 130000 2 5 20 23 N N N N N N N N 
43.  Meenammal 40 8006 24 + – + 8 120000 2 4 10 22 N N N N N N N N 
44.  Selvi 37 8028 22 + + + 10.5 110000 2 4 10 20 N 0.57↑↑ 0.21↓ 0.21↓ N N N N 
45.  Selvarani 45 9265 23 + + + 8.2 120000 2 3 10 22 N 0.57↑↑ 0.24↓ 0.21↓ N N N N 
46.  Palaniyammal 33 9368 22 + – + 8.2 130000 2 5 11 24 N N N N N N N N 
47.  Solayee 50 9570 23 + – + 7.5 140000 2 4 12 25 N N N N N N N N 
48.  Mariyayee 40 5654 21 + – + 7.6 150000 2 6 10 24 N N N N N N N N 
49.  Pappathi 50 9995 20 – + + 8.2 100000 2 3 10 23 N 0.23↓ 0.435↑ 0.40↑ N N N N 
50.  Banu 14 1058 20 – + + 6.5 46000 2 4 10 23 Sple N N N N N N N 
51.  Chellammal 49 2627 25 + + + 8 120000 2 5 10 22 N N N N N N N N 
52.  Vasanthi 40 2048 12 + – + 10.7 110000 2 5 12 24 N N N N N Chronic 
Endometric 
N N 
53.  Siraj Banu 17 10781 19 – – + 6.5 60000 10↑ 5 10 24 N N N N N N N N 
54.  Divya 16 10782 17 – + + 7.5 45000 2 5 10 22 Spleeno 
megaly 
N N N N N N N 
55.  Sajitha 15 10041 21 – – + 7.2 120000 2 4 11 23 N N N N N N N N 
56.  Parvatham 40 10072 28 + + + 8.6 110000 2 4 9 20 N 0.57↑↑ 0.12↓ 0.13↓ N N N N 
57.  Maniyammai 49 1086 26 + – + 8 100000 2 5 10 22 N N N N N N N N 
58.  Vanathi 15 2348 24 + – + 8.2 150000 2 5 11 23 N N N N N N N N 
59.  Kowsalya 13 6801 20 – – + 6.5 100000 2 5 ↑ ↑ N N N N N N N N 
60.  Malar 17 6805 20 – – + 6 50000 10↑ 5 10 22 N N N N N N N N 
61.  Mookayee 45 6820 20 + – + 10 120000 2 5 10 22 N N N N N Chronic 
Endometritis 
N N 
62.  Victoria 16 10465 21 – – + 8.2 120000 2 4 10 21 N N N N N N N N 
63.  Kanagavalli 55 10332 25 – – + 8.8 100000 2 5 10 22 N 0.55↑↑ 0.33↓ 0.40↓ N N N N 
64.  Kowsalya 15 10311 22 + – + 8.4 150000 2 4 10 21 N N N N N N N N 
65.  Maryayee 45 6113 26 + + + 10.2 120000 2 5 10 28 N 0.68↑↑ 0.15↓ 0.12↓ N N N N 
66.  Kokila 14 5414 24 – – + 7.5 100000 2 4 10 25 N N N N N N N N 
67.  Banumary 44 10508 19 – + – 8.2 110000 2 4 10 22 N 0.32 0.28 0.45 N N N N 
68.  Anna Poorani 24 10330 20 – – + 6 50000 2 4 22↑ 23 N N N N N N N N 
69.  Dhanalakshmi 30 10692 22 + + + 7.2 120000 2 5 10 20 N 0.67↑↑ 0.12↓ 0.25↓ N N N N 
70.  Chellayee 55 10887 21 + – + 7.4 155000 2 4 11 23 N N N N N N N N 
71.  Aseena 15 10952 21.4 + – + 7.2 150000 2 4 11 24 N N N N N N N N 
72.  Parvathy 40 10954 20 + – + 8 110000 2 4 10 22 N N N N N Chronic 
Endometritis 
N N 
73.  Sathya 29 10926 26 + + + 10.7 110000 2 4 10 20 N 0.58↑↑ 0.12↓ 0.23↓ N N N N 
74.  Santhamary 15 11468 19 – – + 7 100000 2 4 25.70 26.71 N N N N N N N N 
75.  Kowsalya 13 9266 20 – – + 7.5 120000 2 5 10 22 N N N N N N N N 
76.  Padma 28 11980 22 + + + 8.2 120000 2 4 10 20 N 0.57↑↑ 0.12↓ 0.12↓ N N N N 
77.  Panchu 46 12969 28 + + + 10.4 125000 2 5 11 22 N 0.58↑↑ 0.12↓ 0.13↓ N N N N 
78.  Rajammal 45 10156 23 – – + 8 155000 2 5 10 22 N N N N N N N N 
79.  Jothi Mary 47 12345 24 + + + 8 140000 3 5 11 22 N 0.59↑↑ 0.12↓ 0.13↓ N N N N 
80.  Manikkammal 55 12468 22.4 – – + 7.9 120000 2 4 11 23 N N N N N N N N 
81.  Rajathi 50 12453 28.6 – – + 8.8 110000 2 4 11 22 N N N N N N N N 
82.  Selvi 52 12860 20 – + – 8.8 120000 3 4 10 22 N 0.15 2.3 0.45 N N N N 
83.  Mariyayee 47 12862 22 + – + 10.8 110000 2 4 12 24 N N N N N Chronic 
endometrium 
N N 
84.  Anthoniammal 48 12870 23 + – + 8.2 120000 2 5 11 24 N N N N N N N N 
85.  Sakunthala 49 12850 23 + + – 9 120000 2 4 12 24 N 0.6 0.12 0.22 N N N N 
86.  Chandra 47 12857 20 + – + 10.8 110000 2 4 10 22 N N N N N Chronic 
Endometrium 
N N 
87.  Jeyabarathi 48 12854 22 + + + 7 120000 2 4 11 23 N 0.55↑↑ 0.12↓ 0.22↓ N N N N 
88.  Kala 50 12958 24 + – + 8.3 150000 2 5 11 25 N N N N N N N N 
89.  Kanniammal 51 7091 22 – + + 7.5 120000 2 4 11 22 N N N N N N N N 
90.  Padma 43 6082 23 – + + 8 140000 2 5 11 23 N N N N N N N N 
91.  Pitchaiyammal 44 10923 24 + – + 8.2 160000 2 6 11 24 N N N N N N N N 
92.  Parvatha 42 40423 20 + – + 4.5 180000 2 5 11 25 N N N N N N N N 
93.  Geetha 40 12401 23 – + + 8.3 200000 2 4 11 26 N N N N N N N N 
94.  Kala 55 12400 24 – + + 7.5 220000 2 4 12 24 N N N N N N N N 
95.  Sampoorani 45 10410 26 + + + 10.4 120000 2 4 10 22 N 0.67↑↑ 0.12↓ 0.13↓ N N N N 
96.  Pushpam 14 10444 20 – + + 8.2 240000 2 5 11 23 N N N N N N N N 
97.  Meena 17 10420 19 – – + 6 80000 10 5 10 22 N N N N N N N N 
98.  Thanrapu 50 10415 25 + + + 8.6 110000 2 4 11 22 N 0.77↑↑ 0.12↓ 0.13↓ N N N N 
99.  Banupriya 52 10422 25 + + + 10.2 110000 2 4 10 24 N 0.67↑↑ 0.12↓ 0.13↓ N N N N 
100.  Jothiammal 53 10425 23 – – + 7.5 110000 2 5 10 22 N N N N N N N N 
101.  Parvathy 55 10423 22 – – + 7 120000 2 4 11 23 N N N N N N N N 
102.  Seetha 16 10523 19 – – + 5 50000 13 5 10 20 N N N N N N N N 
103.  Mary 15 10623 20 – – + 7.2 130000 2 5 11 24 N N N N N N N N 
104.  Shanthi 44 10723 22 + + + 10.5 120000 2 4 10 22 N 0.58 0.12 0.22 N N N N 
105.  Kavitha 36 10823 20 – – + 6.8 60000 2 4 20↑ 22 N N N N N N N N 
106.  Madhy 28 10421 24 – – + 7.3 140000 2 5 11 24 N N N N N N N N 
107.  Kala 47 10426 22 + + – 8 110000 2 4 10 22 N 0.56 0.12 0.23 N N N N 
108.  Deepa 48 10424 23.6 – – + 8.6 150000 2 5 11 26 N N N N N N N N 
109.  Divya 49 10428 21.6 – – + 8.4 160000 2 6 15 26 N N N N N N N N 
110.  Jenifer 18 10427 20 – – + 4.5 60000 10↑ 5 10 20 N N N N N N N N 
111.  Vishnu Priya 18 10526 21.4 – – + 7.5 140000 2 7 15 24 N N N N N N N N 
112.  Monina 42 10724 22.2 – – + 7.6 150000 2 8 15 26 N N N N N N  N 
113.  Mariyayee 46 10824 22.4 – – + 4.5 160000 2 5 14 25 N N N N N N N N 
114.  Panchavarnam 50 10826 23.4 – – + 7 120000 2 4 15 24 N N N N N N N N 
115.  Mumtath 52 10419 25 – – + 7.5 140000 2 7 10 25 N N N N N N N N 
116.  Latha 53 10524 26 – – + 7.2 150000 2 8 12 25 N N N N N N N N 
117.  Muthammal 55 15523 26 – – + 7.2 150000 2 8 12 25 N N N N N N N N 
118.  Thavamani 40 15642 22 + – + 8.4 130000 2 5 11 22 N N N N N N N N 
119.  Kathayee 40 1642 23 + + + 8.6 120000 2 4 10 20 N 0.67 0.12 0.22 N N N N 
120.  Paramu 52 16959 24 + + + 10.4 110000 2 4 11 22 N 0.57 0.13 0.23 N N N N 
121.  Parvathy 40 12156 20 + + – 7.0 100000 2 4 10 22 Ascitis 
pl 
effusion 
N N N N N N N 
122.  Suseela 40 16685 20 + + – 7.2 100000 2 5 11 23 Ascitis 
pl 
effusion 
N N N N N N N 
123.  Bharathi 22 16955 23 + – + 7.3 120000 2 4 11 23 N N N N N N N N 
124.  Pharvathy 45 16417 22 + + – 7 120000 2 4 11 24 N 0.56 0.12 0.43 N N N N 
125.  Kathayee 40 16418 24 + – + 7.4 140000 2 5 11 24 N N N N N N N n 
126.  Latha 46 17449 20 + + + 6.2 120000 2 4 11 25 N 0.60 0.22 0.20 N N N N 
127.  Muthamilselvi 53 12123 25 + – + 7.5 150000 2 4 11 25 N N N N N N N N 
128.  Marikamu 34 17496 22 + – + 8 120000 N N N N N N N N Chrone 
Endomertis 
N N N 
129.  Annakamu 40 17558 26 + – + 7.6 160000 2 5 11 25 N N N N N N N N 
130.  Sewahari 44 17659 20 + – + 8.2 110000 2 4 12 22 N N N N N Endometritis N N 
131.  Suseela 48 17521 24 + – + 7.3 120000 2 7 10 22 N N N N N N N N 
132.  Rani 40 17523 22.6 + – + 7.4 130000 2 8 11 23 N N N N N N N N 
133.  Selvarathna 40 17528 23 + + – 10.8 120000 2 5 10 22 N 0.60 0.2 0.2 N N N N 
134.  Chinnapillai 46 10354 20 + + – 8.2 110000 2 5 11 12 Ascitis 
pl 
effusion 
N N N N N N N 
135.  Sundarammal 52 11470 23 + – + 7.2 120000 2 4 10 22 N N N N N N N N 
136.  Sumathi 15 11468 22 + – + 7.8 130000 2 4 10 22 N N N N N N N N 
137.  Shanthi 14 11462 22.4 – – + 8.2 140000 2 4 10 24 N N N N N N N N 
138.  Parvathy 13 11463 22.1 – – + 7.6 150000 2 5 11 25 N N N N N N N N 
139.  Chandra 53 16441 22.3 – – + 7.5 160000 2 6 11 26 N N N N N N N N 
140.  Thangammal 40 19222 22 + + – 5.6 12000 2 5 10 22 N 0.70↑↑ 0.12↓ 0.3↓ N N N N 
141.  Arayee 45 10162 23 + + + 8 120000 2 5 10 20 N 0.65↑↑ 0.22↓ 0.12↓ N N N N 
142.  Mariyaee 46 10112 23 + + + 7 120000 2 4 10 20 N 0.66↑↑ 0.20↓ 0.13↓ N N N N 
143.  Mariamma 40 10182 22 + + + 8.2 20000 2 4 10 22 N 0.56↑↑ 0.42↓ 0.43↓ N N N N 
144.  Chinnammal 42 10181 21 – – + 8.8 120000 2 4 10 22 N 0.57↑↑ 0.23↓ 0.33↓ N N N N 
145.  Divya 16 10180 19.2 – – + 7.5 50000 12↑ 4 10 23 N N N N N N N N 
146.  Latha 17 10210 24 – – + 7.2 125000 2 5 10 24 N N N N N N N N 
147.  Seetha 26 10217 25 – – + 7.4 130000 2 5 12 25 N N N N N N N N 
148.  Kavitha 15 10118 26 + – + 7 140000 2 6 13 26 N N N N N N N N 
149.  Noorjahan 28 10117 22.2 + – + 7.2 150000 2 7 14 25 N N N N N N N N 
150.  Ramzan 48 10178 22 + + – 8.2 110000 2 4 10 22 N 0.67 0.12 0.12 N N N N 
151.  Dilsath 50 10121 23 + + – 8.4 110000 2 5 11 23 N 0.68 0.13 0.23 N N N N 
152.  Yasmin 47 10136 24 + – + 6.5 100000 2 5 15 26 N N N N N N N N 
153.  Chitra 16 10134 23 + – + 7.5 120000 2 5 11 23 N N N N N N N N 
154.  Shanthi 47 10137 21 + + + 8.6 100000 2 4 10 22 N 0.51↑↑ 0.13↓ 0.23↓ N N N N 
155.  Suba 17 10138 24 + – + 7.2 130000 2 5 10 24 N N N N N N N N 
156.  Sudha 38 13014 23 + – + 7 140000 2 5 10 25 N N N N N N N N 
157.  Meena 48 13015 24 – – + 7.4 150000 2 6 11 26 N N N N N N N N 
158.  Lakshmi 47 10141 25 + + + 8 100000 2 4 10 22 N 0.51 0.12 0.23 N N N N 
159.  Brinda 19 10241 20 – – + 6.2 140000 2 4 20 30 N N N N N N N N 
160.  Yashoda 18 10621 25 – – + 7.5 130000 2 7 11 24 N N N N N N N N 
161.  Dhanalakshmi 43 10601 26 – – + 7.6 140000 2 8 11 26 N N N N N N N N 
162.  Afeez Fathima 17 10152 22.2 – – + 8 150000 2 8 11 27 N N N N N N N N 
163.  Rani 16 13016 23.6 – – + 8.2 160000 2 7 11 24 N N N N N N N N 
164.  Mumtaj 47 13018 20 + – + 8.5 100000 2 4 10 22 N N N N TB ⊕ N N N 
165.  Mariyayee 42 13017 26 – + + 8.2 120000 2 4 11 22 N 0.235 0.30 0.40 N N N N 
166.  Sumathy 45 10163 25 + + + 8.6 110000 2 4 11 22 N 0.57 0.12 0.22 N N N N 
167.  Shanthi 19 10164 24 + + + 8.2 120000 2 5 10 23 N 0.67 0.12 0.22 N N N N 
168.  Janci Rani 53 10165 24 + + – 8.5 120000 2 5 10 24 N 0.67 0.13 0.23 N N N N 
169.  Subbulakshmi 50 10166 24.4 – – + 8 120000 2 6 11 23 N N N N N N N N 
170.  Muthulakshmi  38 10143 25 – – + 8.2 140000 2 7 11 24 N N N N N N N N 
171.  Sahayamary 40 10144 22 + – + 6.5 110000 2 5 11 22 N N N N N N N N 
172.  Mary 18 10145 20 – + + 6.2 50000 2 4 10 20 Spleen N N N N N N N 
173.  Brinda 41 10101 21 + + + 8 100000 2 5 10 20 N 0.67 0.12 0.23 N N N N 
174.  Arayee 42 10111 24 + + + 7 100000 2 5 11 22 N 0.68 0.12 0.23 N N N N 
175.  Divya 15 10110 20 – + + 6.5 52000 N N N N Spleen N N N N N N N 
176.  Thara 39 10113 23 – + + 7.5 120000 2 5 11 23 N N N N N N N N 
177.  Lakshmi Priya 45 10114 22 + + – 8 100000 2 5 10 22 Ascitis 
pl 
effusion 
N N N N N N N 
178.  Vanitha 46 10115 23 + + – 8.5 90000 2 4 10 22 Ascitis 
pl 
effusion 
N N N N N N N 
179.  Vidhya 17 13104 22.3 – + + 6.8 130000 2 4 11 24 N N N N N N N N 
180.  Srividhya 47 12105 24 – – + 8.21 90000 2 5 10 22 N 0.51 0.23 0.33 N N N N 
181.  Haseena 18 13106 25 – + + 7.5 150000 2 4 11 24 N N N N N N N N 
182.  Revathy 50 13107 25 – + + 8.2 110000 2 5 10 22 N 0.22 0.45 0.45 N N N N 
183.  Rajalakshmi 51 10116 25 – + + 7.5 150000 2 4 11 24 N N N N N N N N 
184.  Nagalakshmi 39 10119 25 + + – 8.6 110000 2 5 10 20 N 0.67 0.12 0.22 N N N N 
185.  Radha 19 10118 22.3 – + + 7.4 160000 2 5 11 22 N N N N N N N N 
186.  Kaliyammal 40 10126 20 – + + 9.8 62000 N N N N spleen N N N N N N N 
187.  Muthuammal 42 10127 21 + + – 8.2 110000 2 4 10 22 N 0.67 0.12 0.22 N N N N 
188.  Veerammal 45 10128 22 + + + 8.5 120000 2 5 11 22 N 0.47 0.10 0.30 N N N N 
189.  Alagammal 47 10129 22 – – + 6.5 160000 2 4 11 22 N N N N N N N N 
190.  Sumathy 17 11320 23 – – + 6.6 160000 2 5 11 23 N N N N N N N N 
191.  Raniammal 16 11321 24.2 – – + 6.7 160000 2 6 11 24 N N N N N N N N 
192.  Valarmathi 16 11322 20 + + – 6.5 100000 2 4 10 22 N N N N TB⊕ N N N 
193.  Kannagi 43 11323 22 + + + 7.5 120000 2 5 11 23 N N N N TB ⊕ N N N 
194.  Backyalakshmi 40 11324 23 – + + 5.8 120000 2 4 11 24 N 0.23 0.30 0.45 N N N N 
195.  Karpagam 18 11325 22.4 – – + 7 170000 2 4 11 25 N N N N N N N N 
196.  Nagammal 17 11326 22.6 – – + 7.2 180000 2 5 11 26 N N N N N N N N 
197.  Nagalakshmi 37 12220 20 – + + 9.9 67000 2 4 10 22 Spleen⊕ N N N N N N N 
198.  Chandra 16 10221 22.4 – – + 7.3 170000 2 5 12 23 N N N N N N N N 
199.  Vijayalakshmi 38 10222 22 – + + 10 70000 2 4 10 22 spleen⊕ N N N N N N N 
200.  Dhanam 40 13202 23 – – + 7.4 200000 2 6 11 23 N N N N N N N N 
 
ABBREVIATIONS 
AUB    : Abnormal Uterine Bleeding 
FSH    : Follicle Stimulating Hormone 
LH    : Luteinizing Hormone 
GnRH   : Gonadotrophic Releasing Hormone 
TRH    : Thyrotropin Releasing Hormone 
GABA   : Gamma Amino Butyric Acid 
VIP    : Vasoactive Intestinal Peptide 
ERα    : Estrogen Receptor α 
ERβ    : Estrogen Receptor β 
DuB    : Dysfunctional Uterine Bleeding 
PBAC    : Pictorial Blood Assessment Chart 
ITP    : Immune Thrombocytopenic Purpura 
VWD    : Von Willebrand’s Disease 
BT    : Bleeding Time 
aPTT    : Activated Partial Thromboplastin Time 
PT    : Prothrombin Time 
CBC    : Complete Blood Count 
PCR    : Polymerase Chain Reaction 
CA125   : Carcinoembryonic Antigen 
CRH    : Corticotropic Releasing Hormone 
OCPills   : Oral Contraceptive Pills 
BMB    : Breakthrough Menstrual Bleeding 
IUCD    : Intra Uterine Contraceptive Device 
